Acutus Medical, Inc.
AFIB · OTC
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.01 | 0.01 |
| FCF Yield | -245.66% | -147.85% | -726.24% | -318.70% |
| EV / EBITDA | 72.62 | 30.73 | 16.72 | -81.00 |
| Quality | ||||
| ROIC | -1.13% | 13.19% | 0.97% | -1.67% |
| Gross Margin | 14.08% | 7.06% | -8.31% | -0.83% |
| Cash Conversion Ratio | 3.10 | 0.65 | 19.27 | 8.24 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.20% | -29.66% | -31.15% | -27.47% |
| Free Cash Flow Growth | -8.61% | 47.20% | 58.83% | -1.16% |
| Safety | ||||
| Net Debt / EBITDA | 67.53 | 27.74 | 16.04 | -63.93 |
| Interest Coverage | -0.20 | 0.35 | 0.20 | -0.39 |
| Efficiency | ||||
| Inventory Turnover | 3.42 | 1.17 | 0.86 | 0.62 |
| Cash Conversion Cycle | 106.87 | 216.00 | 272.47 | 259.46 |